Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To MOB-015 In EU
T-Reuters
2024-12-11
Moberg Pharma AB (publ) :Moberg Pharma Reports Topline Data In The North American Phase 3 Study And Will Regain Rights To Mob-015 In Eu.Moberg Pharma Ab (Publ) - Mob-015 Did Not Meet Primary Endpoint In Phase 3.Moberg Pharma - Bayer And Co Expressed Mutual Intent To Terminate License Agreement Whereby Moberg Pharma Regains Full Rights For Mob-015 In Eu.